

## Policy Framework

# Reducing the Burden of Neurodegenerative Diseases in Europe and Beyond

2024



European  
Society of  
Medicine

## Executive Summary

The European Society of Medicine emphasizes the urgent need to address the increasing burden of neurodegenerative diseases in Europe. This comprehensive policy framework provides a roadmap for tackling these complex conditions through a multifaceted approach that includes advancements in diagnostics, treatment modalities, long-term management strategies, and equitable access to care. It will be distributed among policymakers and stakeholders in each European nation.

Europe must unite in its efforts to reduce the impact of neurodegenerative diseases. Governments should allocate the necessary resources to support research initiatives, equip healthcare providers with advanced diagnostic and treatment tools, and ensure equitable access to care for all populations, especially the vulnerable and underserved. Collaboration and engagement with stakeholders, including patient advocacy groups, international bodies, and the private sector, are vital for fostering an environment of transparency, trust, and shared responsibility.

Let us commit to a future where neurodegenerative diseases are effectively managed, and health equity is achieved for all citizens. This is our collective responsibility, and it is within our grasp if we act together with determination.

## Key Points

- Neurodegenerative diseases are increasingly prevalent in Europe, posing significant challenges to healthcare systems and economies.
- Establishing a centralized European registry for diagnostic biomarkers and neuroimaging data can enhance early detection of neurodegenerative diseases.
- Gene therapies, stem cell research, and neuroprotective agents have the potential to revolutionize treatment, but are in great need of funding.
- Europe must unite in its efforts to reduce the burden of neurodegenerative diseases.

## Contents

Executive Summary	2
Introduction	4
Epidemiology of Neurodegenerative Diseases	6
Diagnostic Tools and Screening	9
Treatment Modalities	12
Long-Term Management Strategies	15
Access to Care and Health Disparities	17
Stakeholder Engagement and Collaboration	19
Conclusion and Call to Action	21
References	22

## Introduction

Neurodegenerative diseases encompass a range of conditions characterized by the progressive degeneration of the structure and function of the nervous system. They are universally progressive and often debilitating, leading to severe health consequences for individuals and significant burdens on healthcare systems. This policy framework aims to address the complex challenges posed by these diseases through a comprehensive, evidence-based approach.

The historical context of neurodegenerative diseases reveals a landscape marked by significant advancements in understanding and treatment. From the identification of Alzheimer's disease in the early 20th century to the development of disease-modifying therapies, the journey of discovery and innovation has been substantial. Yet, despite these milestones, the burden of neurodegenerative diseases remains heavy. In Europe, the prevalence and incidence of these conditions are rising, with Alzheimer's disease and other dementias leading as some of the most common and impactful neurological disorders. The economic costs associated with neurodegenerative diseases are staggering, with billions of euros spent annually on healthcare expenses, long-term care, and indirect costs such as lost productivity and caregiver burden<sup>1,2</sup>.

The social and individual burden of these diseases is also profound. Quality of life for patients and their families is significantly affected, with caregivers facing immense challenges in providing daily care and support. The current landscape of policies addressing neurodegenerative diseases is varied, as Europe lacks a comprehensive and standardized plan. Healthcare systems across Europe are grappling with the management of these diseases, facing challenges in diagnosis, treatment, and long-term care.

The aim of this framework is to provide a policy framework that outlines a set of priorities to reduce the burden of neurodegenerative diseases. It focuses primarily on dementia-type diseases, demyelinating diseases, motor neuron diseases, and Parkinson's disease. It also discusses some less frequent neurodegenerative diseases such as Huntington's and prion diseases.

The framework will be distributed among key stakeholders, including policymakers, health ministries, and WHO representatives in each European country. The relevance of this policy framework extends beyond Europe, addressing global health challenges and emphasizing the importance of international collaboration. By comparing European trends with global data and highlighting successful international initiatives, this document underscores the need for a unified approach to tackle neurodegenerative diseases.

## Primary Objectives

The recommendations contained in this framework are centered around three primary objectives.

1. Reduce the **prevalence** of neurodegenerative diseases
2. Reduce the **burden** of neurodegenerative diseases
3. Reduce the **cost** of neurodegenerative diseases

The structure of the document is designed to provide a comprehensive overview of the issues at hand, with each section contributing to the overall framework. An interdisciplinary approach is adopted, integrating various fields of study to address the multifaceted nature of neurodegenerative diseases. The collaborative nature of the policy framework is emphasized, encouraging stakeholder engagement and collective action.

This policy framework document serves as a roadmap for reducing the burden of neurodegenerative diseases in Europe and beyond, aiming to improve patient outcomes, support caregivers, and guide stakeholders in the collective effort against these challenging conditions.

### Prevalence of dementia in Europe, by age and sex

Age range	Overall prevalence	Prevalence in females	Prevalence in males
60-64	0.6%	0.9%	0.2%
65-69	1.3%	1.5%	1.1%
70-74	3.3%	3.4%	3.1%
75-79	8%	8.9%	7%
80-84	12.1%	13.1%	10.7%
85-89	21.9%	24.9%	16.3%
90+	40.8%	44.8%	29.7%

Source: [www.alzheimer-europe.org](http://www.alzheimer-europe.org)




## Epidemiology of Neurodegenerative Diseases

The epidemiological profile of neurodegenerative diseases within Europe is a critical concern for public health, characterized by a diverse array of disorders that include Alzheimer's disease, Parkinson's disease, and multiple sclerosis. These conditions are marked by progressive neurological deterioration and present a growing challenge to healthcare systems.

### Prevalence and Incidence Rates in Europe

Neurodegenerative diseases are increasingly prevalent in Europe, posing significant challenges to healthcare systems and economies. The rise in neurodegenerative diseases is influenced by factors such as increased life expectancy, advancements in diagnostic capabilities, and potentially, changes in environmental and lifestyle factors<sup>9</sup>.

Alzheimer's disease is the most common neurodegenerative disorder in Europe, with an estimated prevalence of 5.05% among individuals aged 65 and older. In Germany, approximately 1.6 million people are living with Alzheimer's, while in Italy, about 1.2 million individuals are affected. France reports around 900,000 cases, and the UK has approximately 850,000 cases<sup>3</sup>.



Parkinson's disease affects around 1.2 million people in Europe. The prevalence is highest in Germany, with around 300,000 cases, followed by Italy with 250,000, and the UK with 145,000<sup>4</sup>.

Multiple Sclerosis (MS) has a prevalence of approximately 108 per 100,000 people in Europe. The highest rates are observed in countries like Germany and the UK, with about 120,000 and 110,000 cases, respectively. Scandinavian countries also report high prevalence rates, with Norway and Sweden each having over 10,000 cases<sup>5</sup>.

Amyotrophic Lateral Sclerosis (ALS), though less common, has a notable impact. The prevalence in Europe is approximately 5.2 per 100,000 people. The incidence rates are highest in Italy, with about 2.7 new cases per 100,000 people annually, followed by the Netherlands and the UK, with 2.5 and 2.2 new cases per 100,000 people, respectively<sup>6</sup>.

Huntington's disease (HD) and Prion diseases, though less common than other neurodegenerative disorders, pose significant health challenges in Europe. HD affects approximately 10-12 individuals per 100,000 people, with varying incidence rates across different regions. Prion diseases, including Creutzfeldt-Jakob Disease (CJD), have an incidence rate of about 1-2 cases per million annually. Both diseases have a genetic and infectious basis, respectively, and contribute to the broader burden of neurodegenerative diseases in Europe, necessitating targeted research and healthcare strategies to manage their impact.

### Comparison with Global Statistics

The prevalence of neurodegenerative diseases in Europe is higher than the global average. This discrepancy can be attributed to the region's higher life expectancy and the associated increase in age-related disorders<sup>7</sup>. Epidemiological studies have observed a steady increase in the prevalence of neurodegenerative diseases over the past decades. This trend is anticipated to continue, given the aging demographic of the European population<sup>8</sup>.

### Demographic and Socioeconomic Impact

The prevalence of neurodegenerative diseases is disproportionately higher in older age groups, reflecting the degenerative nature of these conditions. The impact of an aging population is a significant contributor to the increasing prevalence rates<sup>10</sup>. Neurodegenerative diseases impose a substantial economic burden, with costs encompassing medical care, long-term care, and lost productivity. The direct costs of dementia in Europe, for example, are estimated to be over €105 billion annually<sup>11</sup>.

### Projections for the Future Burden

Predictive models suggest a continued rise in the prevalence and incidence of neurodegenerative diseases in Europe, with projections indicating a potential


doubling of cases every 20 years<sup>12</sup>. The anticipated demographic shifts, particularly the increase in the elderly population, are expected to significantly influence the future burden of neurodegenerative diseases<sup>13</sup>.

### Policy Implications

The projected increase in neurodegenerative diseases necessitates a proactive approach to healthcare policy, emphasizing the need for enhanced research, prevention strategies, and healthcare infrastructure to manage the anticipated rise in cases<sup>14</sup>.

### Implications for Healthcare Policy and Planning

The epidemiological data underscore the importance of integrating neurodegenerative diseases into healthcare policy and planning and the need for comprehensive policy frameworks that address the growing prevalence and impact of these conditions. This integration is essential to ensure that healthcare systems are prepared to address the increasing burden of these diseases effectively<sup>15</sup>. As the population ages, the burden of neurodegenerative diseases will continue to rise, presenting significant challenges to healthcare systems and economies. Strategic planning and investment in research and healthcare infrastructure are imperative to mitigate the effects of these diseases and improve the quality of life for affected individuals.



Source: [www.alzheimersresearchuk.org](http://www.alzheimersresearchuk.org)



## Diagnostic Tools and Screening

Early diagnosis of neurodegenerative diseases is crucial for effective management and improving patient outcomes. Current diagnostic practices in Europe face several challenges, including variability in the adoption of advanced diagnostic techniques, lack of standardized screening methods, and limited integration of innovative tools in primary care settings. This section aims to address these challenges by providing policy recommendations to enhance early diagnosis and screening protocols, thereby reducing the burden of neurodegenerative diseases.

### Advancements in Diagnostic Biomarkers and Neuroimaging Techniques

Recent advancements in the identification of genetic markers and the development of blood-based biomarkers have revolutionized the diagnostic landscape for neurodegenerative diseases. These biomarkers offer a non-invasive, cost-effective means of early diagnosis<sup>16</sup>. Additionally, neuroimaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET), have improved the accuracy of disease detection and monitoring. The integration of these diagnostic tools is essential for a comprehensive evaluation.

**Policy Recommendation 1:** Establish a centralized European registry for diagnostic biomarkers and neuroimaging data.

- **Action Plan:**
  - Develop a standardized protocol for the collection, storage, and sharing of biomarker and neuroimaging data.
  - Promote collaboration among research institutions, healthcare providers, and policymakers to populate the registry.
  - Secure funding from EU health programs to support the registry's development and maintenance.
  - Implement data governance policies to ensure patient privacy and data security.

### Standardized Screening Methods in Primary Care Settings

Standardized screening methods and cognitive screening tools are vital for early detection in primary care settings. Current shortcomings include inconsistent screening practices and lack of training for primary care providers.

**Policy Recommendation 2:** Introduce standardized cognitive screening schedules for individuals over the age of 50 in primary care settings.



- **Action Plan:**
  - Review and update existing diagnostic and screening guidelines in each European country to reflect the latest scientific advancements.
  - Provide training programs for primary care providers on the use of these tools and to communicate their importance to patients.
  - Monitor and evaluate the implementation and effectiveness of the screening methods.
  - Allocate funding for the acquisition of necessary screening tools and resources.

<b>Cognitive screening and blood biomarker tests for Alzheimer's disease</b> AMONG ADULTS AGE 65–80		
	<b>Cognitive screening</b>	<b>Blood biomarkers</b>
Very familiar	<b>30%</b>	<b>2%</b>
Somewhat familiar	<b>41%</b>	<b>17%</b>
Not at all familiar	<b>29%</b>	<b>81%</b>
Ever been tested	<b>41%</b>	<b>&lt;1%</b>
Source: University of Michigan National Poll on Healthy Aging, July/August 2023		

### Role of Artificial Intelligence and Digital Health Applications

Artificial intelligence (AI) and digital health applications hold significant potential in enhancing the accuracy and efficiency of screening processes. AI algorithms can analyze complex datasets to identify early markers of neurodegenerative diseases, while digital health platforms can facilitate remote monitoring and patient engagement.

**Policy Recommendation 3:** Integrate AI and digital health applications into the national health systems for enhanced screening and diagnosis.

- **Action Plan:**
  - Establish partnerships with technology firms specializing in AI and digital health.
  - Conduct pilot projects to evaluate the feasibility and effectiveness of AI-driven diagnostic tools.

- Create regulatory frameworks to ensure the safe and ethical use of AI in healthcare.
- Provide training for healthcare providers on the use of AI tools.


### Community-Based Screening Initiatives

Community-based screening programs play a crucial role in raising public awareness and facilitating early detection of neurodegenerative diseases. Successful initiatives have demonstrated the benefits of engaging the public in screening efforts.

**Policy Recommendation 4:** Expand community-based screening initiatives to cover underserved populations.

- **Action Plan:**
  - Collaborate with local health authorities, community organizations, and patient advocacy groups to design and implement screening programs.
  - Utilize mobile health units to reach remote and underserved areas.
  - Conduct public education campaigns to raise awareness about the importance of early diagnosis.
  - Monitor and report on the outcomes of these initiatives to inform future efforts.

By implementing these policy recommendations, Europe can significantly improve early diagnosis and screening protocols, ultimately reducing the burden of neurodegenerative diseases.



## Treatment Modalities

### Introduction to the Current Treatment Landscape

The treatment landscape for neurodegenerative diseases in Europe faces numerous challenges and opportunities for improvement. The overarching goals of treatment for most neurodegenerative diseases are to manage symptoms, slow disease progression, and enhance the quality of life for patients. Despite advancements, there remains a critical need for more effective and comprehensive treatment modalities that can be uniformly applied across Europe.

### Pharmacological Treatments

Pharmacological treatments are a cornerstone of managing neurodegenerative diseases. For Alzheimer's disease, cholinesterase inhibitors and NMDA receptor antagonists are commonly prescribed<sup>17</sup>. Parkinson's disease treatment often involves dopaminergic medications, including levodopa and dopamine agonists<sup>18</sup>. MS management includes immunomodulatory drugs such as interferon-beta and monoclonal antibodies<sup>19</sup>, while ALS treatment is limited to riluzole and edaravone, both of which have modest efficacy<sup>20</sup>. Emerging drug therapies, including gene therapies and neuroprotective agents, show promise but are often hampered by limited availability and high costs. There is an urgent need to ensure equitable access to these novel treatments across Europe.

Huntington's and Prion diseases currently have very limited treatment options, primarily focusing on symptom management rather than cure. For Huntington's, drugs like tetrabenazine help manage chorea, while antidepressants and antipsychotics address psychiatric symptoms. Prion diseases lack effective treatments, with palliative care being the primary approach. The urgency for further research is critical to develop innovative therapies that can halt or reverse disease progression.

### Non-Pharmacological Treatments

Non-pharmacological treatments play a crucial role in managing neurodegenerative diseases. These interventions encompass physical therapy, occupational therapy, speech therapy, and cognitive rehabilitation, each contributing to the holistic care of patients<sup>21</sup>. Lifestyle modifications, such as diet and exercise, have been shown to improve overall health and potentially slow disease progression<sup>22</sup>. Additionally, mental health support is vital for managing the psychological burden associated with these conditions. Multidisciplinary care teams are essential in delivering these comprehensive treatment plans, ensuring that all aspects of patient care are addressed.

### Policy Recommendation 5: Establish a Centralized European Treatment Registry

Creating a centralized European treatment registry is essential for tracking treatment outcomes and sharing best practices across Europe. This registry would facilitate improved data collection, enhance research capabilities, and enable more personalized treatment approaches.

#### Implementation Strategy:

1. **Stakeholder Involvement:** Engage healthcare providers, researchers, patient advocacy groups, and policymakers in the planning and development stages.
2. **Data Privacy:** Establish robust data privacy protocols to protect patient information, complying with GDPR regulations.
3. **Infrastructure Development:** Develop a secure, interoperable digital platform for data collection and sharing.
4. **Pilot Programs:** Initiate pilot programs in selected regions to test the registry's functionality and gather feedback for improvements.
5. **Funding:** Secure funding through EU grants and public-private partnerships to support the registry's development and maintenance.

### Policy Recommendation 6: Increase Funding for Innovative Treatment Research

Investing in research is paramount for the development of new and more effective treatments. Focus areas should include gene therapies, stem cell research, and neuroprotective agents, which hold the potential to revolutionize the treatment landscape.

#### Proposed Funding Mechanisms:

1. **Public-Private Partnerships:** Encourage collaboration between governmental bodies, academic institutions, and pharmaceutical companies to pool resources and expertise.
2. **EU Grants:** Leverage existing EU funding mechanisms, such as Horizon Europe, to support high-impact research projects.
3. **International Collaboration:** Promote international research initiatives to facilitate knowledge exchange and resource sharing, accelerating the development of innovative treatments.

### Policy Recommendation 7: Integrate Advanced Technologies into Treatment Protocols

The integration of advanced technologies, including AI, machine learning, and digital health tools, can optimize treatment plans and monitor patient progress more

effectively. These technologies can analyze large datasets to identify patterns and predict disease progression, facilitating personalized care.

#### Implementation Plan:

1. **Training for Healthcare Professionals:** Develop comprehensive training programs to equip healthcare providers with the skills needed to utilize advanced technologies effectively.
2. **Infrastructure Development:** Invest in the necessary digital infrastructure to support the integration of these technologies into clinical practice.
3. **Regulatory Considerations:** Work with regulatory bodies to establish guidelines and standards for the safe and effective use of AI and digital health tools in treatment protocols.

#### Conclusion

Enhancing treatment modalities for neurodegenerative diseases in Europe is of critical importance. The proposed policies, including the establishment of a centralized European treatment registry, increased funding for innovative research, and integration of advanced technologies, provide a comprehensive framework to improve patient care and outcomes. Medical professionals and governments must collaborate to adopt these policies and invest in the future of neurodegenerative disease treatment. Through a coordinated effort, significant advancements in patient care and outcomes can be achieved, ultimately reducing the burden of these debilitating diseases.

## Long-Term Management Strategies

The burden of neurodegenerative diseases such as Alzheimer's, Parkinson's, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS) is steadily increasing in Europe, necessitating robust long-term management strategies. Effective long-term management is crucial for enhancing the quality of life for patients and alleviating the economic and social burden on healthcare systems. Given the chronic and progressive nature of these diseases, sustainable and adaptive approaches must be developed and implemented to address this growing challenge.

### Current Strategies in Long-Term Management

Current long-term management strategies in Europe encompass a variety of approaches, focusing on multidisciplinary care teams, personalized care plans, and integrated palliative care. Multidisciplinary teams, comprising neurologists, primary care physicians, mental health professionals, and social workers, play a pivotal role in providing comprehensive care. Personalized care plans are tailored to meet the unique needs of each patient, ensuring that medical, psychological, and social aspects are adequately addressed. Moreover, palliative care and support systems are integral to managing symptoms and improving the quality of life for patients and their families.

### Policy Recommendation 8: Invest in Non-Pharmacological Interventions

Given the increasing prevalence of neurodegenerative diseases in Europe, it is crucial to invest in non-pharmacological interventions (NPIs) such as psychosocial interventions, neuromodulation, nutrition, and exercise. Research supported by the EU Joint Programme on Neurodegenerative Disease Research highlights that these interventions can significantly improve patients' quality of life<sup>23</sup>. Studies indicate that physical exercise can reduce cognitive decline by 20-30%, and psychosocial interventions like cognitive behavioral therapy can alleviate symptoms of depression and anxiety in dementia patients<sup>24</sup>.

#### Action Plan:

1. **Allocate funding:** Increase funding for research on NPIs through grants and partnerships with academic institutions.
2. **Pilot programs:** Implement pilot programs across member states to evaluate the effectiveness of NPIs.
3. **Training and education:** Develop training modules for healthcare professionals on the implementation of NPIs.
4. **Public awareness campaigns:** Launch campaigns to educate the public on the benefits of NPIs.

5. **Data collection and analysis:** Establish a centralized database to collect and analyze data from NPI interventions to identify best practices.

### Policy Recommendation 9: Strengthen Integrated Care Delivery

The fragmented nature of current care services for long-term conditions necessitates a shift towards integrated care delivery. The WHO European Region's policy brief supports promoting integrated long-term care to bridge existing divides in care services. Integrated care models have been shown to improve patient outcomes, reduce hospitalizations, and lower healthcare costs.

#### Action Plan:

1. **Policy development:** Formulate policies that mandate integrated care frameworks at the national and local levels.
2. **Stakeholder engagement:** Facilitate dialogues among healthcare providers, patients, and policymakers to identify barriers and opportunities for integration.
3. **Resource allocation:** Allocate resources for the development of integrated care infrastructure, including health IT systems.
4. **Training programs:** Train healthcare professionals in integrated care delivery models and interdisciplinary collaboration.
5. **Monitoring and evaluation:** Develop metrics and systems to monitor the effectiveness and efficiency of integrated care programs.

### Integration and Implementation

Integrating the proposed policies into existing healthcare systems requires careful planning and collaboration among stakeholders. The collaboration of healthcare providers, patients, caregivers, and policymakers is essential for the successful implementation of these strategies. Pilot programs should be initiated to test the effectiveness of the proposed policies, allowing for adjustments and improvements based on real-world outcomes.



## Access to Care and Health Disparities

Health disparities refer to the differences in health outcomes and access to healthcare services among various population groups. In the context of neurodegenerative diseases in Europe, these disparities are particularly pronounced, impacting the timely diagnosis, treatment, and long-term management of conditions such as Alzheimer's disease, Parkinson's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). Uneven distribution of care resources across European regions exacerbates these disparities, necessitating comprehensive policy interventions.

### Disparities in Neurodegenerative Disease Management

Disparities in the management of neurodegenerative diseases are evident, particularly in the context of dementia. The global prevalence of undiagnosed dementia is higher than 60%, with variations in detection among different countries, socioeconomic backgrounds, and community settings compared with residential nursing settings<sup>25</sup>. These disparities are likely to contribute to adverse health outcomes and increased disease burden in underserved populations.

### Impact of Socioeconomic Status on Access to Care

Socioeconomic status (SES) has a substantial impact on the risks of cognitive impairment and dementia. A meta-analysis found an elevated combined risk of cognitive impairment and dementia (relative risk [RR] = 1.31, 95% confidence interval [CI] = 1.16–1.49) in low-SES participants compared with high-SES participants<sup>26</sup>. This suggests that individuals from lower SES backgrounds may face barriers that affect their access to neurodegenerative disease care, potentially leading to disparities in health outcomes.

### Policy Recommendation 10: Equitable Distribution of Resources

To address regional imbalances in care availability, we propose the implementation of policies aimed at equitable resource allocation. This includes the establishment of regional centers of excellence in neurodegenerative disease care, strategically located to serve underserved areas. These centers would provide comprehensive diagnostic, treatment, and long-term care services, supported by telemedicine to extend their reach. Additionally, funding should be allocated to train healthcare professionals in these regions, ensuring a sustainable workforce capable of delivering high-quality care.

#### Action Plan:

1. Conduct a needs assessment to identify underserved regions lacking adequate neurodegenerative disease care services.

2. Establish regional centers of excellence, equipped with advanced diagnostic tools and staffed by multidisciplinary teams.
3. Implement telemedicine programs to extend the reach of these centers to remote and rural areas.
4. Allocate funding for the training and continuous education of healthcare professionals in these regions.
5. Monitor and evaluate the effectiveness of these centers in reducing health disparities and improving patient outcomes.

### Policy Recommendation 11: Data-Driven Approaches to Mitigate Disparities

Data-driven strategies are crucial for identifying and addressing gaps in care provision. We advocate for the collection and analysis of health data to inform policy decisions and improve care delivery. This involves the creation of a centralized European database for neurodegenerative disease patient data, including information on diagnosis, treatment, and outcomes. By analyzing this data, policymakers can identify patterns of disparities and develop targeted interventions to address them.

#### Action Plan:

1. Establish a centralized European database for neurodegenerative disease patient data.
2. Implement standardized data collection protocols across healthcare facilities in Europe.
3. Analyze the collected data to identify patterns of disparities in care provision.
4. Develop targeted interventions based on data analysis to address identified gaps.
5. Monitor and evaluate the effectiveness of these interventions in reducing health disparities.

### Conclusion

Addressing health disparities is critical to improving outcomes for patients with neurodegenerative diseases. Equitable distribution of resources and data-driven approaches are essential components of a comprehensive policy framework. Action and collaboration among stakeholders, including governments, healthcare providers, and patient advocacy groups, are necessary to implement these recommendations and achieve equitable care for all. By addressing health disparities, we can reduce the burden of neurodegenerative diseases and improve the quality of life for affected individuals across Europe.

## Stakeholder Engagement and Collaboration

### Introduction

In the quest to reduce the burden of neurodegenerative diseases across Europe, stakeholder engagement and collaboration are pivotal. Effective engagement of diverse stakeholders ensures that policy recommendations are not only implemented efficiently but also adapted to meet the nuanced needs of different nations. This section outlines a strategic framework for collaborating with key stakeholders in Europe, emphasizing the necessity of a collaborative approach to combat neurodegenerative diseases.

### Identification of Key Stakeholders

**Medical Community:** The involvement of neurologists, general practitioners, and other healthcare professionals is crucial for the early diagnosis, treatment, and long-term management of neurodegenerative diseases. These medical experts are on the frontline, providing essential care and support to patients. Their insights and experiences are invaluable for shaping effective policies and practices.

**Governments and Policy Makers:** National and regional governments play a critical role in the formulation, adoption, and enforcement of health policies. Policymakers must be engaged to ensure that legislative and regulatory frameworks support the objectives of reducing the burden of neurodegenerative diseases. Their commitment is essential for allocating resources, funding research, and ensuring equitable access to care.

**Patient Advocacy Groups:** Including patient voices and experiences is fundamental to creating patient-centered policies. Advocacy groups represent the needs and preferences of patients, ensuring that policies are responsive and empathetic. These groups also play a vital role in raising awareness and providing support and education to patients and their families.

**Research Institutions and Universities:** Collaborations with research institutions and universities are essential for advancing scientific understanding and developing innovative treatments. These entities contribute through research initiatives, clinical trials, and data sharing, helping to translate scientific discoveries into practical solutions.

**Non-Governmental Organizations (NGOs) and International Bodies:** Contributions from NGOs, the World Health Organization (WHO), and European Union health agencies are critical for coordinating efforts at an international level. These organizations provide funding, expertise, and a platform for sharing best practices and strategies across borders.

### Communication and Information Sharing

**Centralized Information Portals:** The development of online platforms for sharing data, research findings, and best practices is vital for fostering collaboration among stakeholders. These portals should be accessible to all stakeholders, providing a repository of valuable information and facilitating real-time communication.

**Regular Reporting and Feedback Mechanisms:** Ensuring transparency and accountability is essential for the success of stakeholder engagement initiatives. Regular reports on progress, challenges, and outcomes should be shared with all stakeholders. Feedback mechanisms should be established to allow stakeholders to voice their opinions, share experiences, and suggest improvements.

**Educational Campaigns and Training Programs:** Informing and educating stakeholders about new policies, diagnostic tools, and treatment methods is crucial for effective implementation. Educational campaigns and training programs should be designed to disseminate knowledge, build capacity, and empower stakeholders to contribute effectively to the collective effort.

In conclusion, effective stakeholder engagement and collaboration are fundamental to reducing the burden of neurodegenerative diseases. By fostering partnerships, ensuring transparent communication, and continuously monitoring and evaluating efforts, we can create a cohesive and dynamic approach to address this growing public health challenge. The collective efforts of all stakeholders will be instrumental in achieving meaningful and lasting improvements in the management and treatment of neurodegenerative diseases.

## Conclusion and Call to Action

The European Society of Medicine emphasizes the urgent need to address the increasing burden of neurodegenerative diseases in Europe. This comprehensive policy framework provides a roadmap for tackling these complex conditions through a multifaceted approach that includes advancements in epidemiology, diagnostics, treatment modalities, long-term management strategies, equitable access to care, and stakeholder engagement.

Policymakers, healthcare providers, research institutions, and community leaders must collaborate to address the challenges posed by neurodegenerative diseases. Prioritizing research and innovation is crucial for developing new diagnostic tools, treatment options, and management strategies that can significantly improve patient outcomes.

Europe must unite in its efforts to reduce the impact of neurodegenerative diseases. Governments should allocate the necessary resources to support research initiatives, equip healthcare providers with advanced diagnostic and treatment tools, and ensure equitable access to care for all populations, especially the vulnerable and underserved.

Research institutions and the private sector must work together to advance the science of neurodegenerative diseases, exploring innovative approaches and sharing best practices across borders. International partnerships can accelerate progress and facilitate the adoption of successful strategies on a global scale.

Let us commit to a future where neurodegenerative diseases are effectively managed, and health equity is achieved for all citizens. This is our collective responsibility, and it is within our grasp if we act together with courage, determination, and foresight.

## References

1. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol*. 2011;21(10):718-779.
2. Wimo A, Jönsson L, Bond J, Prince M, Winblad B; Alzheimer Disease International. The worldwide economic impact of dementia 2010. *Alzheimers Dement*. 2013;9(1):1-11.e3.
3. GBD 2019 Neurological Disorders Collaborator Group. "Global, regional, and national burden of neurological disorders, 1990–2019." *Lancet Neurol*, 2020.
4. Alzheimer Europe. Prevalence of dementia in Europe. 2019.
5. European Parkinson's Disease Association. Parkinson's in Europe. 2020.
6. MS Atlas. Epidemiology of Multiple Sclerosis. 2020.
7. European Journal of Neurology. Epidemiology of ALS in Europe. 2018.
8. World Health Organization. "Neurological disorders: Public health challenges." WHO, 2021.
9. European Brain Council. "The economic cost of brain disorders in Europe." EBC, 2022.
10. Eurostat. "Ageing Europe - statistics on population developments." Eurostat, 2021.
11. Wimo A, et al. "The worldwide economic impact of dementia 2010." *Alzheimers Dement*, 2013.
12. Reitz C, Mayeux R. "Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers." *Biochem Pharmacol*, 2014.
13. United Nations. "World Population Ageing 2019." UN, 2019.
14. European Commission. "EU Joint Programme - Neurodegenerative Disease Research (JPND)." EC, 2023.
15. OECD. "Health at a Glance: Europe 2020." OECD, 2020.
16. Hampel H, O'Bryant SE, Molinuevo JL, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. *Nat Rev Neurol*. 2018;14(11):639-652.
17. Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer's disease drug development pipeline: 2021. *Alzheimers Dement (N Y)*. 2021;7(1):e12179.
18. Schapira AH, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. *Nat Rev Neurosci*. 2017;18(7):435-450.
19. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. *Lancet*. 2018;391(10130):1622-1636.
20. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). *Neurology*. 2009;73(15):1218-1226.



21. Radomski MV, Latham CA. *Occupational therapy for physical dysfunction*. 7th ed. Lippincott Williams & Wilkins; 2013.
22. Petzinger GM, Fisher BE, McEwen S, Beeler JA, Walsh JP, Jakowec MW. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease. *Lancet Neurol*. 2013;12(7):716-726.
23. Alzheimer Europe. 2022 Annual Report of Alzheimer Europe. *Alzheimer Europe*; 2023. Accessed May 23, 2024. [https://www.alzheimer-europe.org/sites/default/files/2023-06/2022\\_annual\\_report\\_of\\_alzheimer\\_europe\\_final.pdf](https://www.alzheimer-europe.org/sites/default/files/2023-06/2022_annual_report_of_alzheimer_europe_final.pdf)
24. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. *Lancet*. 2017;390(10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6.
25. Overcoming gaps in the treatment of neurodegenerative disease. *EBioMedicine*. 2020;60:103088. doi:<https://doi.org/10.1016/j.ebiom.2020.103088>
26. Wang AY, Hu HM, Ou YC, et al. Socioeconomic Status and Risks of Cognitive Impairment and Dementia: A systematic Review and Meta-Analysis of 39 Prospective Studies. *JPAD*. 2022;10(1). doi:<https://doi.org/10.14283/jpad.2022.81>